BERKELEY -
The symposium focus will include molecular biomarkers, experimental diagnostics and liquid biopsies, all of which factor heavily in the development of BriaCell's companion diagnostics under development, including BriaCell's HLA-matching hypothesis and recently-announced Grade I/II biomarkers.
Dr.
'We are grateful to
'As we develop of our novel personalized immunotherapy for advanced breast cancer patients, we are discovering that our technology and biomarkers may be applicable to a number of tumor types. The key is patient selection based on the molecular, cellular and pathologic characteristics of the cancer. We will share these insights with the attendees of this ground-breaking meeting,'
About Frontiers in Academic Pathology: Transplant and Therapeutic Pathology
The course will address critical areas in transplantation and cell-based therapeutics. At the conclusion of the activity, participants will be able to: 1) Describe the use and limitations of diagnostic modalities and biomarkers in the management of patients undergoing cell-based and organ transplantation. 2) Describe recent and developing approaches toward HLA typing. 3) Describe novel clinical applications of cell-based diagnostics and treatments. 4) Describe developing legislation, regulatory and ethical guidelines for the use of human cells or tissue in implantation, transplantation, or transfer into a human recipient.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT, BriaCell's lead candidate, in a Combination Study with immune checkpoint inhibitors such as the
BriaCell currently has a non-exclusive clinical trial collaboration with
BriaCell is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains 'forward-looking information' within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Tel: 1-888-485-6340
Email: farrah@BriaCell.com
(C) 2020 Electronic News Publishing, source